Editas Medicine, Inc. (EDIT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1153518,
    "name": "Editas Medicine, Inc.",
    "stock_name": "Editas Medicine, Inc.",
    "full_name": "Editas Medicine, Inc.",
    "name_url": "stocks-analysis/editas-medicine-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.43",
    "chg": 0.32,
    "chgp": "15.17%",
    "dir": 1,
    "prev_price": "2.11",
    "mcapval": "250.88",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US28106W1036",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.15 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/editas-medicine-inc-1153518-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Editas Medicine Hits New 52-Week High of $4.54, Marking Significant Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/editas-medicine-hits-new-52-week-high-of-454-marking-significant-milestone-3608043",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EditasMedicineI_priceRelatedfactors_3608043.png",
        "date": "2025-10-09 20:21:23",
        "description": "Editas Medicine, Inc. achieved a new 52-week high of USD 4.54 on October 8, 2025, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology industry. Despite this, its one-year performance shows a decline, and it faces challenges in profitability and financial stability."
      },
      {
        "title": "Editas Medicine Hits New 52-Week High at $4.07, Marking Significant Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/editas-medicine-hits-new-52-week-high-at-407-marking-significant-milestone-3601669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EditasMedicineI_priceRelatedfactors_3601669.png",
        "date": "2025-10-07 21:57:07",
        "description": "Editas Medicine, Inc. achieved a new 52-week high of USD 4.07 on October 6, 2025, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology industry. Despite this, its one-year performance shows a decline, and it faces challenging financial metrics."
      },
      {
        "title": "Editas Medicine Hits New 52-Week High of $4.05, Marking Key Milestone",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/editas-medicine-hits-new-52-week-high-of-405-marking-key-milestone-3595670",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/EditasMedicineI_priceRelatedfactors_3595670.png",
        "date": "2025-10-06 17:39:24",
        "description": "Editas Medicine, Inc. achieved a new 52-week high of USD 4.05 on October 3, 2025, despite a challenging year marked by a 26.32% decline in stock performance. The company, with a market cap of USD 251 million, faces significant financial hurdles, including negative return on equity and no dividend yield."
      },
      {
        "title": "Is Editas Medicine, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-editas-medicine-inc-technically-bullish-or-bearish-3547424",
        "imagepath": "",
        "date": "2025-09-20 19:55:00",
        "description": "As of 10 September 2025, the technical trend for Editas Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The weekly RSI shows no signal, but the monthly RSI is bullish. Daily moving averages are bullish, indicating positive short-term momentum. However, the weekly KST is mildly bearish, and the monthly KST is mildly bullish, suggesting mixed signals. The Dow Theory indicates a mildly bullish stance on a weekly basis, but no trend on a monthly basis. The OBV is mildly bullish weekly but mildly bearish monthly, adding to the mixed outlook.\n\nIn terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 10.70% and 9.89% respectively, compared to 1.05% and 2.33% for the index. However, over longer periods, such as the past year and beyond, the stock has underperformed significantly, wit..."
      },
      {
        "title": "Is Editas Medicine, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-editas-medicine-inc-overvalued-or-undervalued-3543800",
        "imagepath": "",
        "date": "2025-09-20 18:29:00",
        "description": "As of 30 March 2016, the valuation grade for Editas Medicine, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.56 and an EV to EBITDA of 0.24, which suggest that the market is pricing the company at a premium despite its losses. Additionally, the ROCE stands at an impressive 142.55%, but this is overshadowed by a concerning ROE of -317.44%, reflecting significant financial distress.\n\nIn comparison to its peers, Kura Oncology, Inc. has a more pronounced EV to EBITDA ratio of -0.3981, while Curis, Inc. stands at -1.1288, both indicating a more favorable valuation relative to Editas. The recent stock performance shows that while Editas has outperformed the S&P 500 on a year-to-date basis with a return of 136.22% compared to 12.22%, it has signif..."
      }
    ],
    "total": 10,
    "sid": "1153518",
    "stock_news_url": "https://www.marketsmojo.com/news/editas-medicine-inc-1153518"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Editas Medicine Hits New 52-Week High of $4.54, Marking Significant Milestone

2025-10-09 20:21:23

Editas Medicine, Inc. achieved a new 52-week high of USD 4.54 on October 8, 2025, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology industry. Despite this, its one-year performance shows a decline, and it faces challenges in profitability and financial stability.

Editas Medicine Hits New 52-Week High at $4.07, Marking Significant Milestone

2025-10-07 21:57:07

Editas Medicine, Inc. achieved a new 52-week high of USD 4.07 on October 6, 2025, marking a significant milestone for the microcap company in the Pharmaceuticals & Biotechnology industry. Despite this, its one-year performance shows a decline, and it faces challenging financial metrics.

Editas Medicine Hits New 52-Week High of $4.05, Marking Key Milestone

2025-10-06 17:39:24

Editas Medicine, Inc. achieved a new 52-week high of USD 4.05 on October 3, 2025, despite a challenging year marked by a 26.32% decline in stock performance. The company, with a market cap of USD 251 million, faces significant financial hurdles, including negative return on equity and no dividend yield.

Is Editas Medicine, Inc. technically bullish or bearish?

2025-09-20 19:55:00

As of 10 September 2025, the technical trend for Editas Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The weekly RSI shows no signal, but the monthly RSI is bullish. Daily moving averages are bullish, indicating positive short-term momentum. However, the weekly KST is mildly bearish, and the monthly KST is mildly bullish, suggesting mixed signals. The Dow Theory indicates a mildly bullish stance on a weekly basis, but no trend on a monthly basis. The OBV is mildly bullish weekly but mildly bearish monthly, adding to the mixed outlook. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 10.70% and 9.89% respectively, compared to 1.05% and 2.33% for the index. However, over longer periods, such as the past year and beyond, the stock has underperformed significantly, wit...

Is Editas Medicine, Inc. overvalued or undervalued?

2025-09-20 18:29:00

As of 30 March 2016, the valuation grade for Editas Medicine, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.56 and an EV to EBITDA of 0.24, which suggest that the market is pricing the company at a premium despite its losses. Additionally, the ROCE stands at an impressive 142.55%, but this is overshadowed by a concerning ROE of -317.44%, reflecting significant financial distress. In comparison to its peers, Kura Oncology, Inc. has a more pronounced EV to EBITDA ratio of -0.3981, while Curis, Inc. stands at -1.1288, both indicating a more favorable valuation relative to Editas. The recent stock performance shows that while Editas has outperformed the S&P 500 on a year-to-date basis with a return of 136.22% compared to 12.22%, it has signif...

View All News